JNJ — Johnson & Johnson
Is JNJ overbought or oversold? Here is the current MarketMoodz read.
Johnson & Johnson (JNJ) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Pharmaceuticals) last closed at $282.55. The rating moved from Neutral to Overbought on November 16, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$282.55
- Last changeMoved from Neutral to Overbought on November 16, 2026
- SectorHealthcare
- IndustryPharmaceuticals
See all overbought Healthcare stocks →
AI analysis
Johnson & Johnson combines a diversified product portfolio with strong cash generation and a conservative balance sheet, positioning it to benefit from defensive flows into large‑cap pharma. Near‑term catalysts include pipeline readouts, targeted M&A to bolster specialty franchises, and steady dividend/share‑repurchase support for total return. Key vulnerabilities include legacy litigation, pricing/reimbursement variability and device exposure to elective procedure cycles. Overall, the company’s scale, cash flow and portfolio flexibility underpin a favorable outlook under base‑case scenarios while regulatory and litigation developments remain primary watch points.
Key factors
- Diversified business mix across pharmaceuticals, medical devices and consumer health providing resilient revenue and cash flow
- Strong balance sheet and free cash flow supporting dividends, share buybacks and targeted M&A
- Large-cap pharma outperformance and defensive inflows amid current market tone favoring stable healthcare names
- Robust late-stage pipeline and ability to acquire specialty franchises to offset product lifecycle pressures
- Positive social sentiment and analyst visibility (recent positive commentary) supporting investor confidence
Risks
- Ongoing legacy litigation exposure and the potential for new product liability cases that could pressure earnings or cash flow
- Pricing and reimbursement pressure from payors and potential policy/regulatory changes impacting margins
- Slower growth or operational disruption in medical devices or consumer segments versus pharma strength
- Macro sensitivity through elective procedures (devices) if economic conditions deteriorate
- Geopolitical, supply-chain or FX headwinds that can impact international revenues and margins
Latest MarketMoodz coverage
- Cramer’s 5 Stocks to Buy During the Market Rotation2026-07-06
- Chip Stocks Rally as Goldman’s M&A Streak Spurs Rotation2026-06-29
- Salesforce reportedly to buy Fin for $3.6B to beef up Agentforce AI2026-06-15
- Goldman Sees Nvidia Upside; What Tech Investors Should Do2026-06-13
- Oracle Earnings Loom: Options Price a 12% Move2026-06-09
See today's live rating, score and targets
Members see the live hourly rating for JNJ — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.